6 results about "Standard treatment" patented technology

This invention belongs to the field of biomedical technology, specifically relating to the discovery and application of biomarkers for predicting the efficacy of immunotherapy in nasopharyngeal carcinoma. This invention provides a reliable combination of 10-gene TLS biomarkers that can effectively predict the pathological TLS status in nasopharyngeal carcinoma tissue. This 10-gene TLS biomarker combination exhibits stable and significant prognostic predictive value: regardless of standard treatment or immunotherapy, a high TLS score can effectively identify patients with better survival outcomes (such as FFS, OS, and DMFS), providing important evidence for individualized risk assessment and treatment strategy selection.

The invention provides a pharmacist clinical ability assessment method and system based on multi-scene self-adaption, and relates to the technical field of pharmacist ability assessment, and the method comprises the steps: configuring a standard diagnosis and treatment process, a mapping rule of an operation event and a diagnosis and treatment step, and a reference weight vector of five ability dimensions for various assessment scenes in advance; performing multi-modal data acquisition on the assessment interaction process of the pharmacist and the virtual patient to obtain a dialogue text sequence; performing semantic coding and context modeling on the dialogue text sequence to obtain a global dialogue abstract vector; obtaining a five-dimensional score vector based on the dialogue text sequence, the diagnosis and treatment step sequence and the pharmaceutical knowledge graph; adopting an adaptive weight network to generate fusion weight vectors of five capability dimensions; and carrying out weighted aggregation on the five-dimensional score vector by using the fusion weight vector to obtain a comprehensive score, and outputting a structured evaluation report. According to the method, the defects of single evaluation scene, shallow scoring dimension and weight logic solidification in the prior art can be overcome.

NOVEL COMPOSITIONS FOR DISRUPTING BIOFILMS Abstract of the Disclosure Compositions and methods are provided for disrupting biofilms formed by microbial organisms. In accordance with one embodiment such compositions are used in conjunction with standard treatment for use on chronic wounds. In one embodiment the biofilm disrupting composition comprises a nuclease and aurine tricarboxylic acid. The biofilm disrupting compositions disclosed herein can be used in conjunction with a therapeutic pharmaceutical composition comprising standard antibiotics. NOVEL COMPOSITIONS FOR DISRUPTING BIOFILMS Abstract of the Disclosure 20 26 20 51 40 30 J un 2 02 6 N O V E L C O M P O S I T I O N S F O R D I S R U P T I N G B I O F I L M S 2 0 2 6 2 0 5 1 4 0 3 0 J u n 2 0 2 6 A b s t r a c t o f t h e D i s c l o s u r e

The application discloses a kind of standard diagnosis and treatment scheme automatic construction system of multiple typing of disease, it is characterized in that, comprising: data preprocessing module;ADRG grouping module;Core project automatic identification module;Regression tree grouping module.The present application technology combines clinical medical knowledge and machine learning method, identifies the standard treatment scheme of multiple typing under disease, forms disease knowledge base, to provide reference for the audit of fraud insurance case.The present application uses the medical knowledge of ADRG under the premise, uses some logical judgment to screen out the core project under disease to the medical data, uses regression tree to group important features.The grouping result and the clinical interpretability of the feature of grouping are strong, and the accuracy is also higher.In the process of grouping, both consider the project involved in diagnosis and treatment scheme, and can use model to realize efficient grouping.

The application relates to the medical technical field, in particular to application of sulfasalazine in preparation of a medicine for treating primary biliary cholangitis (PBC) which is poorly responsive to ursodeoxycholic acid (UDCA), aiming at the clinical problem that about 40% of PBC patients are poorly responsive to the first-line drug UDCA, have high disease progression risk and limited second-line treatment options, and providing a new treatment use of the mature drug sulfasalazine. Through prospective clinical research, it is confirmed that, on the basis of UDCA standard treatment, combined use of sulfasalazine (1.5g / day, a treatment course of 48 weeks) can significantly improve liver biochemical indexes of UDCA non-responders, including alkaline phosphatase and gamma-glutamyltransferase, and 62.5% of the patients reach composite biochemical response. The application provides a new, effective, safe and highly accessible second-line treatment strategy for PBC patients who are poorly responsive to UDCA, and has a good clinical application prospect.

This application discloses a method and related products for analyzing drug safety and efficacy based on target trial simulation. The method preprocesses clinical data from patients with prostate disease to obtain standardized data; then, it simulates a target trial on the standardized data according to preset conditions to determine the simulation trial dataset and analysis parameter table. The simulation trial dataset is a set of standardized data used to simulate clinical trial analysis; the analysis parameter table is a set of parameter configurations recording the preset conditions used in the target trial simulation process; the preset conditions include inclusion / exclusion criteria, treatment grouping rules, follow-up rules, and bias control strategies; finally, it performs drug safety and efficacy analysis on the simulation trial dataset and analysis parameter table to obtain the drug safety and efficacy analysis results. This avoids the time-consuming, labor-intensive, and difficult-to-conduct aspects of traditional clinical trials, achieving high efficiency and low cost while providing relatively rigorous and reliable results to support the needs of rapid clinical decision-making.